GlobeNewswire

World Conference on Lung Cancer Sunday Press Conference: Introducing New Awards and Global Guidelines

Dela

YOKOHAMA, Japan, Oct. 15, 2017 (GLOBE NEWSWIRE) -- The first press briefing at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new awards and innovations that encourage and support the treatment of lung cancer and other thoracic malignancies; these include the recognition of outstanding care teams, introduction of new guidelines for nurses and fostering the next generation of researchers.

The press conference began with a welcome message from Conference Co-Presidents Dr. Hisao Asamura and Dr. Keunchil Park, who have worked tirelessly to make this year's conference in Yokohama a major success.

The first Cancer Care Team Award recognizes exceptional patient care
The IASLC Foundation is awarding its first-ever Cancer Care Team Award to multidisciplinary cancer care teams across the globe who go above and beyond to provide the highest-quality patient care. The award was proposed by Dr. Matthew Holman and his wife, Marilyn, a lung cancer survivor. Jill Feldman, a lung cancer survivor and advocate from the United States, introduced the award by telling her story and sharing why this award is particularly meaningful to her.

"My team at Rush University has always been patient-centered and is so deserving of this award, along with the other awardees today," said Jill Feldman. "Amazing things are possible when teams across disciplines work together to put the patient first. I am grateful to the IASLC Foundation for introducing an award that encourages this kind of extraordinary teamwork."

Teams at the following institutions were recognized with the award:

  • Guangdong Lung Cancer Institute (China)
  • Neotorax - Oncologia D'or (Brazil)
  • Instytut Gruzlicy i Chorób Pluc w Warszawie (Poland); Klinika Chorób Wewnetrznych, Pneumonologii i Alergologii, Samodzielny Publiczny szpital Kliniczny w Warszawie (Poland); Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie w Warszawie (Poland)
  • Johns Hopkins Hospital - Sidney Kimmel Cancer Center (USA)
  • Rush University Medical Center (USA)

New guidelines for nurses provide best practices for immunotherapy treatment
At last year's WCLC in Vienna, the IASLC Nursing and Allied Health Committee identified the need for educational support for those caring for lung cancer patients receiving immunotherapy. During today's press conference, Kim Rohan of the United States and Anne Fraser of New Zealand unveiled the resulting guidelines for immunotherapy. The guidelines are an invaluable resource to nurses and cover the life-threatening adverse effects patients may experience during immunotherapy treatment including gastrointestinal, dermatologic, endocrine, ocular, hepatic, neurological and pulmonary toxicities.

"These guidelines are unique in that they are the result of international collaboration," said Anne Fraser. "As immunotherapy treatment continues to be utilized more frequently, the guidelines will be essential to helping nurses understand and mitigate the potential side effects."

IASLC Mentorship Award participants speak to the value of mentorship
The IASLC International Mentorship Program is a professional development and education program for early-career thoracic malignancy-focused physicians and researchers from economically developing countries. Thirteen mentees were selected for the 2017 program, representing specialties from medical oncology to pulmonology and hailing from Argentina, China, India, Indonesia, Malaysia, Pakistan, Saudi Arabia, Serbia and Thailand. Some of the world's leading figures in lung cancer will provide mentorship and guidance during the WCLC, as well as host the mentees at their home institutions for a week.

A number of mentors shared their experiences with the program and underscored the value of mentorship, including Fiona Blackhall of the United Kingdom, Ross Camidge of the United States, Nir Peled of Israel and Mary O'Brien of the United Kingdom.

For Prof. Blackhall, the benefits of mentorship include the ability to inspire the next generation of oncologists and cancer researchers, serve as a female role model in medicine and highlight areas of unmet need in lung cancer research. Prof. Peled found that there were mutual benefits of working with his mentee, as he has been able to enlarge his team network. Dr. Camidge, who is based in Denver, discussed his long-distance collaboration with his mentee, Harry Ren of China. They jointly diagnosed a patient who then traveled to Denver for a clinical trial, demonstrating the value of global collaboration.

Mary O'Brien also spoke to why mentorship is so critical for young professionals in the field. "Medicine is a profession traditionally taught as an apprenticeship, learning from and watching senior doctors. Medicine has changed and much is not taught through books and other sources of information. We need to remember the power of human contact. A strong mentorship scheme will bring the best out of young doctors, talents that are both obvious and hidden," said Dr. O'Brien.

Livestreams of the daily press conferences are available here.

About the WCLC
The World Conference on Lung Cancer (WCLC) is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting over 6,000 researchers, physicians and specialists from more than 100 countries. The goal is to disseminate the latest scientific achievements; increase awareness, collaboration and understanding of lung cancer; and to help participants implement the latest developments across the globe. Organized under the theme of "Synergy to Conquer Lung Cancer," the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit wclc2017.iaslc.org.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Contacts:             
Hillary Wasserman 
Senior Associate
HWasserman@GroupGordon.com
+1 732-778-1896

Becky Bunn, MSc
Public Relations Manager
Becky.Bunn@IASLC.org
+1 720-254-9509



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IASLC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum